Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Upstream Bio, Inc.. The associated price target remains the same with $42.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kate Dellorusso has given his Buy rating due to a combination of factors, including compelling efficacy data for verekitug in patients with comorbid asthma and chronic rhinosinusitis with nasal polyps, where the drug substantially reduced the need for systemic steroids or sinus surgery and improved multiple disease endpoints. She also highlights that these benefits, alongside preserved lung function and meaningful asthma control signals, suggest verekitug could deliver more comprehensive airway disease management than first-generation TSLP inhibitors.
In addition, Dellorusso underscores that verekitug’s broad impact on Type 2 inflammation biomarkers supports a differentiated, first-in-class mechanistic profile that could translate into durable clinical benefits and a competitive positioning in respiratory and inflammatory diseases. Combined with a maintained $42 price target, the company’s current valuation, cash runway, and upside potential from further development and commercialization opportunities collectively justify her continued Buy recommendation on Upstream Bio, Inc.
In another report released on May 14, Mizuho Securities also maintained a Buy rating on the stock with a $50.00 price target.